GlassScriptPhysician profile
Danielle N Rand
NPI 1588916225
$12,275.62
in general payments reported to CMS, 2019-2025
38 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,606 · 2022: $2,921 · 2023: $3,822 · 2024: $1,542 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,336 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,260 · Education: $128 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,335.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,260.00 |
| Education | $127.98 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,837.24 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Novartis Pharmaceuticals Corporation | $1,258.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $993.53 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $881.46 | 2021-2025 | |
| Pfizer INC. | $876.42 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $798.51 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $798.07 | 2021-2025 | Lifevest |
| Amgen INC. | $574.74 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $510.76 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $508.59 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $467.61 | 2021-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.50 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $396.75 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $264.65 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $187.36 | 2022-2023 | Optimizer |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $149.73 | 2021-2025 | Nexletol |
| Tactile Systems Technology INC | $138.36 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Kiniksa Pharmaceuticals, LTD. | $130.50 | 2021-2023 | Arcalyst |
| Vifor Pharma, INC. | $119.28 | 2021-2022 | |
| Cvrx, INC. | $117.72 | 2022 | |
| United Therapeutics Corporation | $99.54 | 2021-2025 | Tyvaso |
| Azurity Pharmaceuticals, INC. | $87.63 | 2023-2025 | Edarbi, Edarbi |
| Alnylam Pharmaceuticals INC. | $76.17 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $67.84 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $64.51 | 2023-2024 | |
| Corcept Therapeutics | $57.86 | 2023 | Korlym |
| Lundbeck LLC | $45.31 | 2021 | |
| Abiomed | $43.59 | 2023 | Impella |
| Altathera Pharmaceuticals LLC | $42.81 | 2023 | Sotalol Hydrochloride |
| Boston Scientific Corporation | $32.08 | 2021 | |
| Atricure, INC. | $30.81 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Lexicon Pharmaceuticals, INC. | $30.23 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $26.74 | 2023 | Injectafer |
| Kestra Medical Technology Services, INC. | $24.42 | 2023 | Assure Wcd |
| Abbott Laboratories | $23.22 | 2023 | Mitraclip |
| Amryt Pharma Holdings LTD | $17.32 | 2021 | |
| Preventice Services, LLC | $17.12 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Rand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.